Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome
- PMID: 30261105
- DOI: 10.1002/jso.25246
Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome
Abstract
Background: The objective of the current study was to identify the risk of early vs late recurrence of well-differentiated (G1) neuroendocrine liver metastasis (NELM) after curative-intent resection.
Methods: Patients who underwent curative-intent resection for well-differentiated NELM were identified from a multi-institutional database. Clinicopathological details, as well as the long-term overall (OS) and recurrence free survival (RFS) were obtained and compared. The optimal cutoff value to differentiate early and late recurrence was determined to be 1 year based on trend curve analysis.
Results: Among the 548 patients undergoing curative resection for NELM, 162 patients had a well-differentiated NELM. After a median follow-up of 69 months, 59 (36.4%) patients had tumor recurrence; 23 (39.0%) patients recurred within 1 year (early recurrence) after surgery, while 36 (61.0%) recurred after 1 year (late recurrence). Early recurrence was associated with worse outcome vs late recurrence (5-year OS, 72.4% vs 92.0%; P = 0.020) and no recurrence (5-year OS, 72.4% vs 100.0%; P < 0.001). In addition, postrecurrence survival was worse within 36 months after recurrence among patients who recurred early compared with patients who recurred late (survival after recurrence at 36 months: early recurrence, 71.6% vs late recurrence, 91.4%; P = 0.047), although survival was comparable at 60 months (early recurrence, 71.6% vs late recurrence, 70.0%; P = 0.304). On multivariable analysis, nonfunctional neuroendocrine tumors (hazard ratio [HR], 4.4; 95% confidence interval [CI], 1.2-16.7; P = 0.029) and lymph node metastasis (HR, 3.6; 95% CI, 1.1-11.1; P = 0.028) were independent risk factors for early recurrence, whereas lymph node metastasis (HR, 3.0; 95% CI, 1.2-7.8; P = 0.020) and R1 resection (HR, 3.9; 95% CI, 1.4-10.5; P = 0.008) were independently associated with late recurrence.
Conclusions: Roughly, one-third of patients with well-differentiated NELM experienced a recurrence following curative-intent surgery. Among patients who recurred, two out of five patients recurred within 1 year after surgery. Early recurrence of well-differentiated NELM was associated with the hormone functional status and lymph node metastasis.
Keywords: early; late; neuroendocrine liver metastasis; recurrence; well differentiated.
© 2018 Wiley Periodicals, Inc.
Similar articles
-
Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment.J Gastrointest Surg. 2017 Nov;21(11):1821-1830. doi: 10.1007/s11605-017-3490-2. Epub 2017 Jul 20. J Gastrointest Surg. 2017. PMID: 28730354
-
Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis.J Surg Oncol. 2018 Feb;117(2):171-181. doi: 10.1002/jso.24832. Epub 2017 Sep 20. J Surg Oncol. 2018. PMID: 28940257
-
The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study.J Gastrointest Surg. 2019 Mar;23(3):484-491. doi: 10.1007/s11605-018-3862-2. Epub 2018 Jul 6. J Gastrointest Surg. 2019. PMID: 29980977
-
Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments.J Gastroenterol. 2025 Jan;60(1):1-9. doi: 10.1007/s00535-024-02166-z. Epub 2024 Nov 15. J Gastroenterol. 2025. PMID: 39547997 Free PMC article. Review.
-
Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas - a single center experience with ten patients.Langenbecks Arch Surg. 1999 Aug;384(4):370-7. doi: 10.1007/s004230050216. Langenbecks Arch Surg. 1999. PMID: 10473858 Review.
Cited by
-
Surgical management of pancreatic neuroendocrine liver metastases.J Gastrointest Oncol. 2020 Jun;11(3):590-600. doi: 10.21037/jgo.2019.11.02. J Gastrointest Oncol. 2020. PMID: 32655938 Free PMC article. Review.
-
Risk Factors and Predictive Score Model for Early Recurrence After Curative Surgery in Patients With Poorly Differentiated Gastrointestinal Neuroendocrine Neoplasms.Front Surg. 2021 Sep 16;8:703138. doi: 10.3389/fsurg.2021.703138. eCollection 2021. Front Surg. 2021. PMID: 34604293 Free PMC article.
-
Neuroendocrine liver metastases: a contemporary review of treatment strategies.Hepatobiliary Surg Nutr. 2020 Aug;9(4):440-451. doi: 10.21037/hbsn.2020.04.02. Hepatobiliary Surg Nutr. 2020. PMID: 32832495 Free PMC article. Review.
-
Multimodal therapy with aggressive hepatectomy, everolimus, and octreotide for metastatic pancreatic neuroendocrine neoplasm enables 10-year survival.Clin J Gastroenterol. 2022 Dec;15(6):1136-1144. doi: 10.1007/s12328-022-01689-3. Epub 2022 Aug 29. Clin J Gastroenterol. 2022. PMID: 36038805
-
Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.Expert Rev Anticancer Ther. 2019 Dec;19(12):1029-1050. doi: 10.1080/14737140.2019.1693893. Epub 2019 Nov 27. Expert Rev Anticancer Ther. 2019. PMID: 31738624 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical